
    
      Phase 3 Study of the Efficacy and Safety of Squalamine Lactate Ophthalmic Solution 0.2% Twice
      Daily in Subjects with Neovascular Age-Related Macular Degeneration Methodology: Phase III,
      multicenter, randomized, double-masked, placebo-controlled study conducted over 9 months

      (Screening/Baseline to Week 36): Patients will be randomly assigned to one of 2 treatment
      groups in a 1:1 ratio:

        -  Squalamine lactate ophthalmic solution, 0.2% BID + ranibizumab every 4 weeks

        -  Placebo ophthalmic solution BID + monthly ranibizumab every 4 weeks
    
  